Key Highlights

  • The FDA pushed the action date on Capricor Therapeutics (NASDAQ:CAPR) deramiocel application from August 22 to November 22, 2026, after treating new material as a major amendment.
  • A July 29, 2026 advisory committee voted 3 to 9 on whether evidence showed substantial effectiveness for Duchenne cardiomyopathy, and the vote carries no binding weight.
  • Cash, equivalents and marketable securities totaled about USD 237.9 million at June 30, 2026, versus roughly USD 318.1 million at year-end 2025, and no Revenue has been booked.
  • The second-quarter net loss reached about USD 40.7 million, or USD 0.70 per share, compared with USD 25.9 million a year earlier.

Review Narrows Toward Upper Limb Function

Capricor is a clinical-stage biotechnology company working on deramiocel, a cell therapy aimed at Duchenne muscular dystrophy. The FDA issued a complete response letter in July 2025, resumed review in March 2026 after the Phase 3 HOPE-3 readout, and set an August 22 date. On August 24, 2026, Capricor Therapeutics (NASDAQ:CAPR) disclosed that a submission containing 24-month open-label extension data counted as a major amendment, which moved the date to November 22, 2026. The company asked regulators to weigh a narrower indication centered on upper limb function, HOPE-3's primary endpoint, whereas the original priority review in 2025 had concentrated on heart function. That change matters because the timeline now rests on the revised submission rather than the earlier one.

Mixed Trial Evidence and a Financing Timeline

HOPE-3 hit its primary upper limb measure, PUL 2.0, with a p-value of 0.029, and the findings appeared in a peer-reviewed medical journal. A statistical model error, however, shifted the left ventricular ejection fraction result from a p-value of 0.04 to 0.09. Regulators inspected the company in July 2026 and issued one observation on a Form 483, which Capricor answered. The company says its cash covers at least 12 months, yet operating expenses reached about USD 42.9 million in the second quarter, and launch preparation is moving more slowly until regulatory clarity improves.

Unverified Growth Screen and Binary Regulatory Risk

A screen labeled Capricor an aggressive small cap, citing a 48.91% one-year EPS change and a price near USD 8.27, up 0.36%. Both are unconfirmed published data. With no revenue and a widening loss, any EPS improvement could reflect a small or odd base, and it could not be matched to a filing. Market Capitalization was not verified. An FDA decision, a further delay, an arbitration with a distribution partner expected this fall and continuing cash burn are the main risks. Biotech shares often gap on regulatory news in either direction, so a 0.36% screen move says little about the likely reaction. Investors should also watch for the third-quarter report and any update on the FDA inspection feedback.

Where Things Stand

The current target is November 22, 2026, but nothing guarantees a decision on that day, and the FDA has already shown it can extend dates. The 3 to 9 vote concerned cardiomyopathy and does not bind the agency, while the amended filing leans on upper limb data that met its primary endpoint. Cash of about USD 237.9 million buys time, though losses are widening and there is no product revenue. A decision, a delay or another information request are all possible outcomes. Launch timing depends on that result, so the next letter from the agency is the key marker.